louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06509386: Effects of Portrayals of Successful Treatment and Role Fulfillment on Mental Illness Stigma
Official title: Randomized Vignette Experiment on the Effects of Portrayals of Successful Treatment and Role Fulfillment on Mental Illness Stigma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mental Illness
Lead sponsor: Yale University
Sponsor class: OTHER
First posted: 2024-07-19
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study aims to measure levels of mental illness stigma based on successful treatment and societal role fulfillment of the individual portrayed with mental illness.

Detailed description: This study aims to measure levels of mental illness stigma based on successful treatment and societal role fulfillment of the individual portrayed with mental illness. This study utilizes eight vignettes portraying two different mental illnesses (depression and schizophrenia), with one vignette giving no details about role fulfillment or treatment, another giving no details about role fulfillment but successful treatment, another giving details on role fulfillment but no treatment, and last giving details on both role fulfillment and successful treatment.

Eligibility criteria: Inclusion Criteria:

* All adults who consider Buyende District their primary residence and who are capable of providing consent

Exclusion Criteria:

* Minors younger than 18 years of age
* Persons who do not consider Buyende District their primary place of residence

Primary outcomes:
measure: Personal Acceptance Scale (PAS)
timeFrame: One year. For each interview, approximately 60 minutes.
measure: Broad Acceptance Scale (BAS)
timeFrame: One year. For each interview, approximately 60 minutes.
measure: Attributed Stigma Scale
timeFrame: One year. For each interview, approximately 60 minutes.
Secondary outcomes:
Other outcomes:
Locations:
city: Iganga
country: Uganda
facility: Empowerment to Heal - Uganda
Study officials:
affiliation: Yale University
name: Yang Jae Lee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01872286: Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2
Official title: A Double-center Randomized Head-to-head Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Intestinal Diseases
Gastrointestinal Hemorrhage
Keywords: Capsule Endoscopy
Lead sponsor: Changhai Hospital
Sponsor class: OTHER
Collaborators: name: Second Military Medical University
name: Ministry of Education, China
First posted: 2013-06-07
Enrollment: 53
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: DIAGNOSTIC

Brief summary: Capsule endoscopy has been shown to be the first-line endoscopic procedure for small bowel disease. This study was aimed to compare the performance between the frequency-altering AKE-1 capsule and the Pillcam SB2 in patients with suspected small bowel disease.


Eligibility criteria: Inclusion Criteria:

* obscure gastrointestinal bleeding
* chronic diarrhea
* suspected Crohn's disease
* chronic abdominal pain
* neoplastic lesions of small bowel

Exclusion Criteria:

* patients with any contraindication to capsule endoscopy

Primary outcomes:
measure: judgement of normal or abnormal of gastrointestinal tract
timeFrame: 5 weeks after the examination
Secondary outcomes:
measure: complete small-bowel examination rate
timeFrame: 5 weeks after the examination
measure: diagnostic yield
timeFrame: 5 weeks after the examination
measure: total recording time
timeFrame: 5 weeks after the examination
measure: gastric transit time
timeFrame: the comparison was completed 5 weeks after the examination
measure: small-bowel transit time
timeFrame: the comparison was completed 5 weeks after the examination
measure: total number of images captured
timeFrame: the comparison was completed 5 weeks after the examination
Other outcomes:
measure: number of adverse events as a measure of safety
timeFrame: 2 months after the examination
Locations:
city: Wuhan
country: China
facility: Wuhan Union Hospital
state: Hubei
city: Shanghai
country: China
facility: Shanghai Changhai Hospital
state: Shanghai
Study officials:
affiliation: Changhai Hospital
name: Zhao-Shen Li, Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Liao Z, Gao R, Xu C, Li ZS. Indications and detection, completion, and retention rates of small-bowel capsule endoscopy: a systematic review. Gastrointest Endosc. 2010 Feb;71(2):280-6. doi: 10.1016/j.gie.2009.09.031.
citation: Cave DR, Fleischer DE, Leighton JA, Faigel DO, Heigh RI, Sharma VK, Gostout CJ, Rajan E, Mergener K, Foley A, Lee M, Bhattacharya K. A multicenter randomized comparison of the Endocapsule and the Pillcam SB. Gastrointest Endosc. 2008 Sep;68(3):487-94. doi: 10.1016/j.gie.2007.12.037. Epub 2008 Apr 14.
citation: Dolak W, Kulnigg-Dabsch S, Evstatiev R, Gasche C, Trauner M, Puspok A. A randomized head-to-head study of small-bowel imaging comparing MiroCam and EndoCapsule. Endoscopy. 2012 Nov;44(11):1012-20. doi: 10.1055/s-0032-1310158. Epub 2012 Aug 28.
Clinical trial NCT03195686: Efficacy of PLEM100(Inbody®) in Children
Official title: Efficacy of PLEM100(Inbody®) to Measure the the Sedation Level in Pediatric Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Development, Child
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2017-06-22
Enrollment: 60
Sex: ALL
Minimum age (years): 3
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric patients to be operated under general anesthesia, aged from 3 to 6 years

Brief summary: Evaluation of efficacy of PLEM100(Inbody®) in measuring the sedation level in pediatric patients

Detailed description: The investigators plan to gather the basic data relevant to measurement of the level of consciousness/sedation in pediatric patients with developing brain by using PLEM100(Inbody®)

PLEM100 (Inbody®) is a medical equipment to measure, based on phase lag entropy algorithm, the level of patient consciousness, which is expressed by PLE score ranging from 0 (burst suppression or deep sedated) to 100 (awake).

In this study, pediatric patients aged from 3 to 6 years old who undergo total intravenous general anesthesia are chosen as target subjects. The investigators measure how PLE score changes during 1) anesthesia induction, 2) anesthesia maintenance, 3) emergence from anesthesia. Then, the PLE score would be validated by analyzing the correlation with the consciousness level expressed in University of Michigan Sedation Scale (UMSS).

Eligibility criteria: Inclusion Criteria:

* Pediatric patients to be operated under general anesthesia, aged from 3 to 6 years
* Written Consent is available from a parent who has been explained about the study
* Elective surgery

Exclusion Criteria:

* Patients who cannot be attached by PLEM100 (Inbody®) sensors to the forehead or the side of the head
* Patients Having Cerebral Vascular Diseases in the past or present
* Patients with Developmental delay
* Patients to be admitted to intensive care unit or sedated after receiving operation
* Patients who researchers decide are not eligible to be enrolled in the study because of various factors including clinical test results.

Primary outcomes:
measure: PLE100 score (0 to 100)
timeFrame: baseline and end of surgery
Secondary outcomes:
measure: The level of consciousness measured in University of Michigan Sedation Scale (UMSS)
timeFrame: baseline and end of surgery
measure: pharmacodynamic model
timeFrame: baseline and end of surgery
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Hee-Soo Kim
state: Soul-t'ukpyolsi
Study officials:
affiliation: Seoul National University Hospital
name: Hee-Soo Kim, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Jang YE, Ji SH, Lee JH, Kim EH, Kim JT, Kim HS. The relationship between the effect-site concentration of propofol and sedation scale in children: a pharmacodynamic modeling study. BMC Anesthesiol. 2021 Sep 9;21(1):222. doi: 10.1186/s12871-021-01446-y.
Clinical trial NCT00937586: Prostate Cancer Prospective Cohort
Official title: Prostate Cancer Prospective Cohort
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Prostate Cancer
Keywords: Metastatic Prostate Cancer
Prostate Cancer Risk Assessment
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: Johns Hopkins University
name: National Cancer Institute (NCI)
name: Wake Forest University
First posted: 2009-07-13
Enrollment: 1937
Sex: MALE
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with newly diagnosed prostate cancer are being recruited for this study from Siteman Cancer Center radiation oncology, medical oncology and urology clinics.

Brief summary: The overall purpose of this research is to determine if certain genes increase the chance of developing prostate cancer and once diagnosed increase the chance of the prostate cancer spreading to other parts of the body.

Detailed description: DNA will be isolated from each person and then studied for the presence of certain genes that may increase the chance of developing prostate cancer. Certain genes will also be studied in patients with known prostate cancer to determine if they increase the chance of cancer spreading to other parts of the body and decrease one's chance of being cured. Small differences in genes can slightly affect their ability to function. While these differences are normal, they may influence the way the cancer responds to therapy. An understanding of which genes increase (or decrease) the chance of being cured of a disease, such as prostate cancer, will improve our ability to take care of patients more effectively.

A second purpose of this study is to collect blood and cancer tissue for future studies. While the small differences in genes may be the best marker of bad cancer, it is also possible that proteins in blood or tumor may be a better marker.

Eligibility criteria: Inclusion Criteria:

* Newly diagnosed patients: 1. newly diagnosis of prostate cancer 2. untreated except for neoadjuvant systemic therapy.

Exclusion Criteria:

* Newly diagnosed patients: 1. inability to give informed consent

Primary outcomes:
measure: Ability to recognize increased risk of metastatic prostate cancer based on specific genetic polymorphisms.
timeFrame: At the time of prostate cancer diagnosis
Secondary outcomes:
measure: Ability to predict risk for treatment failure based on analysis of specific polymorphisms.
timeFrame: At the time of prostate cancer diagnosis
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Bettina Drake, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00940186: Clinical Pharmacokinetics Study on Pikamilone
Official title: Clinical Pharmacokinetics Study on Pikamilone
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Lead sponsor: Chinese Academy of Sciences
Sponsor class: OTHER_GOV
First posted: 2009-07-15
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 15 male subjects and 15 female subjects were enrolled in this study. They were divided into three groups by random and each group contained 5 male and 5 female subjects.

Brief summary: Study on the phamacokinetics of Pikamilone in healthy Chinese subject and provide informations for further phase II study.


Eligibility criteria: Inclusion Criteria:

* nonsmokers and in good health
* weight: BMI: 19-24
* written informed consent was finished.

Exclusion Criteria:

* disease
* taking any drug, alcohol, foods containing caffeine, or grapefruits and juice before study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Shenyang
country: China
facility: the second hospital to liaoning university of TCM
state: Liaoning
Study officials:
affiliation: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
name: D F Zhong, PH.D
role: STUDY_CHAIR
References:
Clinical trial NCT01760486: State-wide Health Approach to Increase Reach and Effectiveness: Study 3
Official title: Using a State-wide Initiative to Disseminate Effective Behavioral Weight Loss Strategies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Lead sponsor: The Miriam Hospital
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2013-01-04
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators have shown that adding an internet behavioral weight loss program to a statewide campaign improves weight loss outcomes. However, our follow-up data suggest that once the intervention is stopped, participants begin to experience weight regain. Thus, the purpose of this project is extend this line of work and pilot test health coaches and monetary incentives for weight loss maintenance. The investigators hypothesize that coaching and incentives will improve longer-term weight outcomes.


Eligibility criteria: Inclusion Criteria:

1. Body Mass Index \>=25kg/m2
2. English speaking

Exclusion Criteria:

1. Health problems that make weight loss or unsupervised exercise unsafe
2. Current pregnancy or plan to become pregnant in the next 12 months
3. Planned relocation
4. Previous participation in Shape Up Rhode Island research studies

Primary outcomes:
measure: weight change from month 2 (i.e. immediately following the weight loss phase) to the 12 month follow-up assessment measured on a digital scale to the nearest 0.1 kilogram
timeFrame: 2 to 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Providence
country: United States
facility: The Miriam Hospital's Weight Control and Diabetes Research Center
state: Rhode Island
Study officials:
affiliation: The Miriam Hospital
name: Rena R Wing, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05989386: Outcomes of High-volume Saline Irrigation VS Povidone-Iodine Solution Cleaning of IOWI in Preventing SSIs in Emergency Laparotomies
Official title: Outcomes of High-volume Saline Irrigation VS Povidone-Iodine Solution Cleaning of Intraoperative Incision Wound in Preventing Surgical Site Infections in Emergency Laparotomies: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Surgical Site Infection
Surgical Wound
Surgical Incision
Emergency Laparotomies
Laparotomies
Post Operative Wound Infection
Wound Infection
Seroma
Lead sponsor: Dow University of Health Sciences
Sponsor class: OTHER
First posted: 2023-08-14
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The goal of this clinical trial is to compare the outcomes of High-volume saline irrigation vs Povidone-iodine solution cleaning of the intraoperative incision wound in preventing superficial surgical site infections in patients undergoing emergency laparotomies. The main question it aims to answer are:

* Incidence of SSI after intervention
* Length of hospital stay

Participants will be randomly assigned to two groups receiving either of the two groups:

Group A: 1000ml of IOWI with saline solution prior to incision closure Group B: The incisional wound will be closed conventionally without irrigation.

Researchers will compare groups A( experimental group) and B (control group) to compare the incidence of superficial surgical site infections after intervention.


Eligibility criteria: Inclusion Criteria:

* • Patients undergoing emergency laparotomy under the care of surgical-6 unit of Dr. Ruth K. M. Pfau Civil Hospital Karachi

  * The age of patients should be between 18-60 years old.

Exclusion Criteria:

* Diabetic patients
* Immune-suppressed patients
* Patients taking steroids
* Patients undergoing chemo-radiotherapy.
* Pregnant females
* Previous abdominal surgery within the last 30 days.
* Presence of concurrent abdominal wall infections.
* Trauma Laparotomies
* Large Bowel perforations

Primary outcomes:
measure: Incidence of Superficial Surgical site infections
timeFrame: Upto 4 weeks post-operatively
Secondary outcomes:
measure: Length of Hospital Stay
timeFrame: Upto 4 weeks post-operatively
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Dr. Ruth K. M. Pfau Civil Hospital Karachi
state: Sindh
Study officials:
affiliation: Dr. Ruth F. M. Pfau Civil Hospital Karachi
name: Omer Bin Khalid, Assist Prof.
role: PRINCIPAL_INVESTIGATOR
affiliation: Dr. Ruth F. M. Pfau Civil Hospital Karachi
name: Imrana Zulfikar, Professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT01379963: A Retrospective Observational Study of Hemoglobin Levels in Patients With Renal Anemia Treated With Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)
Official title: Non-interventional Study of Six-month Retrospective Reporting of Hemoglobin Levels in Patients With Renal Anaemia Who Are Treated With MIRCERA® (Methoxy-polyethylene-glycol-epoetin Beta)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anemia, Kidney Disease, Chronic
Lead sponsor: Hoffmann-La Roche
Sponsor class: INDUSTRY
First posted: 2011-06-23
Enrollment: 780
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with renal anemia on treatment with Mircera

Brief summary: This retrospective observational study will evaluate the hemoglobin levels in patients with renal anemia over 6 months treatment with Mircera (methoxy polyethylene glycol-epoetin beta).


Eligibility criteria: Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Renal anemia treated with Mircera for at least 6 months before entering study

Exclusion Criteria:

* Patients who refuse or are incapable of giving their written informed consent to retrospective data collection

Primary outcomes:
measure: Percentage of Participants Who Achieved a 3-month Hemoglobin Level Stabilization in the Range of 11-12 Grams Per Deciliter (g/dL)
timeFrame: Up to 6 months
Secondary outcomes:
measure: Percentage of Participants Who Achieved a 6-month Hemoglobin Level Stabilization in the Range of 11-12 g/dL
timeFrame: Up to 6 months
Other outcomes:
Locations:
city: Arta
country: Greece
facility: General Hospital of Artas; Nephrology
city: Athens
country: Greece
facility: Pantokrator Private Clinic; Nephrology
city: Athens
country: Greece
facility: Attikon Center; Nephrology
city: Athens
country: Greece
facility: Athinaiki Private Clinic
city: Athens
country: Greece
facility: Kyanos Stavros Private Hospital; Nephrologic Clinic
city: Athens
country: Greece
facility: Iaso General Private Clinic; Nephrology
city: Daphni-athens
country: Greece
facility: Iatriko Athinon Clinic Dafnis; Nephrology Department
city: Egaleo
country: Greece
facility: Timios Stavros Clinic; Nephrology Department
city: Patra
country: Greece
facility: Kyanous Stavros of Patras, Renal Disease Therapy Unit
city: Patra
country: Greece
facility: Olympion Therapeytirion; Nefrology
city: Pireus
country: Greece
facility: Iasis Private Clinic
city: Polygyros
country: Greece
facility: General Hospital Of Chalkidikis; Dialysis Center Unit
city: Thessaloniki
country: Greece
facility: Diavalkaniko Kentro; Nephrology
city: Thessaloniki
country: Greece
facility: General Hospital of Thessalonikis G.Papanikolaou; Nephrology
city: Thessaloniki
country: Greece
facility: Alfa Nefrodynamiki; Nefrology
city: Volos
country: Greece
facility: Thessaliki Nossileytiki; Nephrology
city: Volos
country: Greece
facility: General Hospital of Volos; Nephrology
Study officials:
affiliation: Hoffmann-La Roche
name: Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT02193763: Bedside Ultrasound Assisted Pediatric Lumbar Puncture
Official title: Bedside Ultrasound Assisted Pediatric Lumbar Puncture--A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Infant/ Neonate Lumbar Puncture
Keywords: pediatric
lumbar puncture
ultrasonography
efficacy
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2014-07-18
Enrollment: 0
Sex: ALL
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a prospective, randomized study evaluating the efficacy of bedside ultrasound assisted lumbar puncture in pediatric patients

Detailed description: Comparison of bedside ultrasound assisted lumbar puncture to traditional anatomical landmark approach in neonates and young infants requiring lumbar puncture

Eligibility criteria: Inclusion Criteria:

* Any patient 0-12 months old requiring a lumbar puncture in the pediatric emergency department or inpatient pediatric floor is eligible to participate in the study

Exclusion Criteria:

* previous back surgeries
* parent/ guardian inability to understand informed consent
* parent/guardian refusal of informed consent.

Primary outcomes:
measure: Traumatic lumbar puncture
timeFrame: up to 24 hours
measure: Unsuccessful lumbar puncture
timeFrame: average of <1hour
Secondary outcomes:
measure: Hospital length of stay
timeFrame: average of <7days
Other outcomes:
measure: clinical outcome/ hospital course of the patient
timeFrame: 30days
measure: number of lumbar puncture attempts
timeFrame: average of <1hour
measure: time to completion of lumbar puncture
timeFrame: average of <1hour
measure: perception of the clinician on the usefulness of bedside ultrasound if used
timeFrame: up to 24 hours
Locations:
city: Oak Lawn
country: United States
facility: Advocate Christ Medical Center
state: Illinois
Study officials:
affiliation: Wake Forest University Health Sciences
name: Samuel Lam, MD
role: PRINCIPAL_INVESTIGATOR
References: